Neuralink’s plans for a brain implant designed to restore vision have gained attention following a statement from founder Elon Musk. He claimed the Blindsight device could enable complete vision restoration for individuals who are blind, including those blind from birth, and stated that the technology is ready pending regulatory approval. However, current information indicates that the technology is still in early development stages. As of November 2, ClinicalTrials.gov does not list any studies focused on vision restoration by Neuralink. The company has ongoing trials related to brain-computer interfaces and speech restoration, but none for Blindsight.
Neuralink has not clarified the regulatory approval Musk referenced or provided details on a planned human study. The FDA granted Blindsight Breakthrough Device Designation in September 2024, which aids in the development of devices for serious conditions but does not equate to approval. The company has not released independent evidence showing that Blindsight can restore functional vision. As Neuralink moves toward potential human testing, it must clarify the regulatory process and disclose trial details. The ability of Blindsight to deliver the promised vision restoration remains unproven.
Source: drug-dev.com · Image: Polina Anikeeva for National Science Foundation by Credit: National Science Foundation, Public domain, via Wikimedia Commons
Use the database as your supply chain compass →
